Literature DB >> 4425913

Daunorubicin and the heart.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4425913      PMCID： PMC1612550     

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  9 in total

1.  Cardiac ultrastructural changes induced by daunorubicin therapy.

Authors:  L M Buja; V J Ferrans; R J Mayer; W C Roberts; E S Henderson
Journal:  Cancer       Date:  1973-10       Impact factor: 6.860

2.  [Toxicologic study and experimental antitumor activity of rubidomycin (13,057 R.P.)].

Authors:  R Maral; G Bourat; R Ducrot; J Fournel; P Ganter; L Julou; F Koenig; J Myon; S Pascal; J Pasquet; P Populaire; Y de Ratuld; G H Werner
Journal:  Pathol Biol       Date:  1967-10

3.  Daunorubicin in acute myelocytic leukaemia.

Authors:  J S Malpas; R B Scott
Journal:  Lancet       Date:  1969-03-01       Impact factor: 79.321

4.  Cardiac toxicity of daunorubicin.

Authors:  G Bonadonna; S Monfardini
Journal:  Lancet       Date:  1969-04-19       Impact factor: 79.321

5.  Cardiac toxicity of daunorubicin.

Authors:  A M Marmont; E Damasio; F Rossi
Journal:  Lancet       Date:  1969-04-19       Impact factor: 79.321

6.  Proceedings: Daunorubicin cardiac toxicity in children with acute lymphocytic leukemia.

Authors:  J F Halazun; H R Wagner; J F Gaeta; L F Sinks
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

7.  Daunomycin: a cardiotoxic agent.

Authors:  L E Ainger; J Bushore; W W Johnson; J Ito
Journal:  J Natl Med Assoc       Date:  1971-07       Impact factor: 1.798

8.  [Electrocardiographic study on 34 children treated with daunomycin].

Authors:  C Romano; R Pongiglione; E Raffaelli; A Fossati
Journal:  Minerva Pediatr       Date:  1970-01-14       Impact factor: 1.312

9.  Daunorubicin (NSC 82151) in the treatment of advanced childhood lymphoblastic leukemia.

Authors:  B Jones; J F Holland; A R Morrison; S L Lee; L F Sinks; J Cuttner; A Rausen; F Kung; H J Pluss; F I Haurani; R B Patterson; J Blom; E O Burgert; J H Moon; L Chevalier; A Sawitsky; M M Albala; R J Forcier; G Falkson; O Glidewell
Journal:  Cancer Res       Date:  1971-02       Impact factor: 12.701
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.